Interstitial lung diseases: never forget to think about it in primary care

References

• Stanel S, Rivera-Ortega P. Present and future perspectives in early diagnosis and monitoring for progressive fibrosing interstitial lung diseases. Front Med. 2023;10:1114722. doi: 10.3389/fmed.2023.1114722
   Web of Science ®Google Scholar
• Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2022;205(9):e18–e47. doi: 10.1164/rccm.202202-0399ST
   PubMed Web of Science ®Google Scholar
• National Clinical Guideline Centre (UK). Diagnosis and management of suspected idiopathic pulmonary fibrosis: idiopathic pulmonary fibrosis. London: Royal College of Physicians (UK); 2013. Nice Clinical Guidelines, n63.
   Google Scholar
• Khor YH, Ng Y, Barnes H, et al. Prognosis of idiopathic pulmonary fibrosis without anti-fibrotic therapy: a systematic review. Eur Respir Rev. 2020; 29(157):190158. doi: 10.1183/16000617.0158-2019
   PubMed Web of Science ®Google Scholar
• Faverio P, Piluso M, De Giacomi F, et al. Progressive fibrosing interstitial lung diseases: prevalence and characterization in two Italian referral centers. Respiration. 2020;99(10):838–845. doi: 10.1159/000509556
   PubMed Web of Science ®Google Scholar
• Guler SA, Winstone TA, Murphy D, et al. Does systemic sclerosis–associated interstitial lung disease burn out? Specific phenotypes of disease progression. Ann Am Thorac Soc. 2018;15(12):1427–1433. doi: 10.1513/AnnalsATS.201806-362OC
   PubMed Web of Science ®Google Scholar
• Nasser M, Larrieu S, Si-Mohamed S, et al. Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study). Eur Respir J. 2021;57(2):2002718. doi: 10.1183/13993003.02718-2020
   PubMed Web of Science ®Google Scholar
• Richeldi L, Launders N, Martinez F, et al. The characterisation of interstitial lung disease multidisciplinary team meetings: a global study. ERJ Open Res. 2019;5(2):00209–2018. doi: 10.1183/23120541.00209-2018
   PubMedGoogle Scholar
• Simpson T, Barratt SL, Beirne P, et al. The burden of progressive fibrotic interstitial lung disease across the UK. Eur Respir J. 2021;58(1):2100221. doi: 10.1183/13993003.00221-2021
   PubMed Web of Science ®Google Scholar
• Copeland CR, Lancaster LH. Management of progressive fibrosing interstitial lung diseases (PF-ILD). Front Med. 2021;8:743977. doi: 10.3389/fmed.2021.743977
   Web of Science ®Google Scholar
• Rajan SK, Cottin V, Dhar R, et al. Progressive pulmonary fibrosis: an expert group consensus statement. Eur Respir J. 2023;61(3):2103187. doi: 10.1183/13993003.03187-2021
   PubMed Web of Science ®Google Scholar
• Dhooria S, Agarwal R, Sehgal IS, et al. Spectrum of interstitial lung diseases at a tertiary center in a developing country: a study of 803 subjects. PLoS One. 2018;13(2):e0191938. doi: 10.1371/journal.pone.0191938
   PubMed Web of Science ®Google Scholar
• Cottin V. Treatment of progressive fibrosing interstitial lung diseases: a milestone in the management of interstitial lung diseases. Eur Respir Rev. 2019;28(153):190109. doi: 10.1183/16000617.0109-2019
   PubMed Web of Science ®Google Scholar
• Reiseter S, Gunnarsson R, MogensAaløkken T, et al. Progression and mortality of interstitial lung disease in mixed connective tissue disease: a long-term observational nationwide cohort study. Rheumatology. 2018;57(2):255–262. doi: 10.1093/rheumatology/kex077
   PubMed Web of Science ®Google Scholar
• Zamora-Legoff JA, Krause ML, Crowson CS, et al. Progressive decline of lung function in rheumatoid arthritis–associated interstitial lung disease. Arthritis Rheumat. 2017;69(3):542–549. doi: 10.1002/art.39971
   PubMed Web of Science ®Google Scholar
• Lamas DJ, Kawut SM, Bagiella E, et al. Delayed access and survival in idiopathic pulmonary fibrosis: a cohort study. Am J Respir Crit Care Med. 2011;184(7):842–847. doi: 10.1164/rccm.201104-0668OC
   PubMed Web of Science ®Google Scholar
• Richeldi L, Cottin V, Du Bois RM, et al. Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS® trials. Respir med. 2016;113:74–79. doi: 10.1016/j.rmed.2016.02.001
   PubMed Web of Science ®Google Scholar
• Kolb M, Richeldi L, Behr J, et al. Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. Thorax. 2017;72(4):340–346. doi: 10.1136/thoraxjnl-2016-208710
   PubMed Web of Science ®Google Scholar
• Jo HE, Glaspole I, Grainge C, et al. Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian idiopathic pulmonary fibrosis registry. Eur Respir J. 2017;49(2):1601592. doi: 10.1183/13993003.01592-2016
   PubMed Web of Science ®Google Scholar
• Raman L, Stewart I, Barratt S, et al. Nintedanib for non-IPF progressive pulmonary fibrosis: 12-month outcome data from a real-world multicentre observational study. ERJ Open Res. 2023;9(2):00423–2022. doi: 10.1183/23120541.00423-2022
   PubMedGoogle Scholar
• Nalysnyk L, Cid-Ruzafa J, Rotella P, et al. Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur Respir Rev. 2012;21(126):355–361. doi: 10.1183/09059180.00002512
   PubMedGoogle Scholar
• Flaherty KR, Wells AU, Cottin V, et al. INBUILD trial investigators. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381(18):1718–1727. doi: 10.1056/NEJMoa1908681
   PubMed Web of Science ®Google Scholar
• Kim E, Elicker BM, Maldonado F, et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J. 2010;35(6):1322–1328. doi: 10.1183/09031936.00092309
   PubMed Web of Science ®Google Scholar
• Zamora- Legoff JA, Krause ML, Crowson CS, et al. Progressive decline of lung function in rheumatoid arthritis–associated interstitial lung disease. Arthritis Rheumat. 2017;69(3):542–549. doi: 10.1002/art.39971
   PubMed Web of Science ®Google Scholar
• Dawson J. Predictors of progression of HRCT diagnosed fibrosing alveolitis in patients with rheumatoid arthritis. Ann Rheumatic Dis. 2002;61(6):517. doi: 10.1136/ard.61.6.517
   PubMed Web of Science ®Google Scholar
• Jacob J, Hirani N, van Moorsel CHM, et al. Predicting outcomes in rheumatoid arthritis related interstitial lung disease. Eur Respir J. 2019;53(1):1800869. doi: 10.1183/13993003.00869-2018
   PubMed Web of Science ®Google Scholar
• Cano-Jimenez E, VazquezRodriguez T, Martín-Robles I, et al. Diagnostic delay of associated interstitial lung disease increases mortality in rheumatoid arthritis. Sci Rep. 2021;11(1):9184. doi: 10.1038/s41598-021-88734-2
   PubMed Web of Science ®Google Scholar
• Wells AU, Brown KK, Flaherty KR, et al. What’s in a name? That which we call IPF, by any other name would act the same. Eur Respir J. 2018;51(5):1800692. doi: 10.1183/13993003.00692-2018
   PubMed Web of Science ®Google Scholar
• Michalski JE, Schwartz DA. Genetic risk factors for idiopathic pulmonary fibrosis: insights into Immunopathogenesis. J Inflamm Resp. 2021 Jan 5;13:1305–1318. doi: 10.2147/JIR.S280958
   PubMed Web of Science ®Google Scholar
• Narváez J, Aburto M, Seoane-Mato D, et al. Criterios de cribado de la enfermedad pulmonar intersticial difusa asociada a la artritis reumatoide: propuesta de expertos basada en metodología Delphi. Reumatología Clínica. 2023;19(2):74–81. doi: 10.1016/j.reuma.2021.12.006
   PubMed Web of Science ®Google Scholar
• Reynolds C, Feary J, Cullinan P. Occupational contributions to interstitial lung disease. Clin Chest Med. 2020;41(4):697–707. doi: 10.1016/j.ccm.2020.08.015
   PubMed Web of Science ®Google Scholar
• García-Sancho C, Buendía-Roldán I, Fernández-Plata MR, et al. Familial pulmonary fibrosis is the strongest risk factor for idiopathic pulmonary fibrosis. Respir med. 2011 Dec;105(12):1902–1907.
   PubMed Web of Science ®Google Scholar
• Doyle TJ, Hunninghake GM, Rosas I. Subclinical interstitial lung disease: why you should care. Am J Respir Crit Care Med. 2012 Jun 1;185(11):1147–1153.
   PubMed Web of Science ®Google Scholar
• Borie R, Kannengiesser C, Antoniou K, et al. European Respiratory Society statement on familial pulmonary fibrosis. Eur Respir J. 2023 Mar 16;61(3):2201383. doi: 10.1183/13993003.01383-2022
   PubMed Web of Science ®Google Scholar
• Zaman T, Lee J. Risk factors for the development of idiopathic pulmonary fibrosis: a review. Curr Pulmonol Rep. 2018 Dec;7(4):118–125. doi: 10.1007/s13665-018-0210-7
   PubMedGoogle Scholar
• Hoyer N, Prior TS, Bendstrup E, et al. Risk factors for diagnostic delay in idiopathic pulmonary fibrosis. Respir Res. 2019;20(1):103. doi: 10.1186/s12931-019-1076-0
   PubMed Web of Science ®Google Scholar
• Vasakova M, Mogulkoc N, Sterclova M, et al. Does timeliness of diagnosis influence survival and treatment response in idiopathic pulmonary fibrosis? Real-world results from the EMPIRE registry. Eur Respir J. 2017;50. doi: 10.1183/1393003.congress-2017.PA4880
   Web of Science ®Google Scholar
• Lamas DJ, Kawut SM, Bagiella E, et al. Delayed access and survival in idiopathic pulmonary fibrosis: a cohort study. Am J Respir Crit Care Med. 2011;184(7):842–847. doi: 10.1164/rccm.201104-0668OC
   PubMed Web of Science ®Google Scholar
• Pritchard D, Adegunsoye A, Lafond E, et al. Diagnostic test interpretation and referral delay in patients with interstitial lung disease. Respir Res. 2019;20(1):253. doi: 10.1186/s12931-019-1228-2
   PubMed Web of Science ®Google Scholar
• Bonella F, Wijsenbeek M, Molina-Molina M, et al. European idiopathic pulmonary fibrosis patient charter: a missed opportunity. Eur Respir J. 2016;48(1): 283–284. doi: 10.1183/13993003.00604-2016
   PubMedGoogle Scholar
• Schoenheit G, Becattelli I, Cohen AH. Living with idiopathic pulmonary fibrosis: an in depth qualitative survey of European patients. Chron Respir Dis. 2011;8(4):225–231. doi: 10.1177/1479972311416382
   PubMed Web of Science ®Google Scholar
• Silva M, Fernandes A, Pereira AR, et al. Awareness towards the main ILD among primary care physicians. Multidis Res Med. 2022;17:848. doi: 10.4081/mrm.2022.848
   PubMed Web of Science ®Google Scholar
• Cottin V, Cordier JF. Velcro crackles: the key for early diagnosis of idiopathic pulmonary fibrosis? Eur Respir J. 2012;40(3):519–521. doi: 10.1183/09031936.00001612
   PubMed Web of Science ®Google Scholar
• van der Sar IG, Jones S, Clarke DL, et al. Patient reported experiences and delays during the diagnostic pathway for pulmonary fibrosis: a multinational European survey. Front Med. 2021;8:711194. doi: 10.3389/fmed.2021.711194
   Web of Science ®Google Scholar
• Borchers AT, Chang C, Keen CL, et al. Idiopathic pulmonary fibrosis—an epidemiological and pathological review. Clin Rev Allergy Immunol 2011; 40(2):117–134. doi: 10.1007/s12016-010-8211-5
   PubMed Web of Science ®Google Scholar
• Spagnolo P, Ryerson CJ, Putman R, et al. Early diagnosis of fibrotic interstitial lung disease: challenges and opportunities. Lancet Respir Med. 2021;9(9):1065–1076. doi: 10.1016/S2213-2600(21)00017-5
   PubMed Web of Science ®Google Scholar
• D Zibrak JD, Price D. Interstitial lung disease: raising the index of suspicion in primary care. 2014;24(1):14054 NPJ Prim Care Respir Med. doi: 10.1038/npjpcrm.2014.54
   PubMed Web of Science ®Google Scholar
• Bermudo G, Suárez-Cuartin G, Rivera-Ortega P, et al. Different faces of idiopathic pulmonary fibrosis with preserved forced vital capacity. Archivos de Bronconeumología. 2022 Feb;58(2):135–141.
   PubMed Web of Science ®Google Scholar
• Adegunsoye A. Diagnostic delay in idiopathic pulmonary fibrosis: where the rubber meets the road. Ann ATS. 2019 Mar;16(3):310–312. doi: 10.1513/AnnalsATS.201812-883ED
   Google Scholar
• Molina-Molina M, Aburto M, Acosta O, et al. Importance of early diagnosis and treatment in idiopathic pulmonary fibrosis. Expert Rev Respir Med. 2018;12(7):537–539. doi: 10.1080/17476348.2018.1472580
   PubMed Web of Science ®Google Scholar